Feng Jiang

US Patent:

20120302629, Nov 29, 2012

Filed:

Jul 28, 2010

Appl. No.:

13/388610

Inventors:

Shaomeng Wang - Saline MI, US
Feng Jiang - Ann Arbor MI, US
Jianting Long - Guangzhou, CN
Longchuan Bai - Ann Arbor MI, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI

International Classification:

A61K 31/11
C12Q 1/68
A61P 35/00
A61K 31/337
A61P 29/00
A61P 31/00
A61P 7/00
A61P 35/02
G01N 33/574
A61P 37/00

US Classification:

514449, 435 79, 435 611, 514700

Abstract:

The present invention provides a biomarker for selecting a patient for treatment with gossypol, wherein the biomarker comprises an elevated expression level of c-Myc, Mcl-1, or combination thereof, relative to the normal expression level of c-Myc, Mcl-1, or combination thereof. The present invention also provides methods for targeting patients for treatment with gossypol, wherein the patient has a disease, condition, or disorder that overexpresses c-Myc, Mcl-1, or combination thereof. The present invention also provides methods for treating or ameliorating a disease, condition, or disorder in a patient comprising determining the expression level of c-Myc, Mcl-1, or combination thereof in the patient and administering gossypol to the patient. In certain embodiments of the invention, the disease is cancer, and the cancer cells show elevated expression levels of c-Myc compared to non-cancerous cells. The invention also provides methods for overcoming Mcl-1-mediated chemoresistance comprising administering gossypol to a patient in need thereof.